盘龙药业吴杰：在行业变革中坚持创新与全产业链布局

Core Viewpoint - The pharmaceutical industry is undergoing significant changes, presenting challenges and pressures for companies. Panlong Pharmaceutical emphasizes innovation and research and development as key to its strategy, achieving stable growth despite market fluctuations [1][3]. Industry Overview - The pharmaceutical industry is facing dual challenges from market dynamics and policy changes. Companies must adapt to reforms in medical insurance payments, normalized centralized procurement, and stricter industry regulations [3]. - The aging population is driving a rigid demand for healthcare, forming the underlying logic for long-term industry growth. Additionally, the rising health awareness among the public is leading to a trend of younger and more normalized health consumption [3]. Company Strategy - Panlong Pharmaceutical has established a comprehensive industry chain covering "herb planting—drug research and development—manufacturing—commercial distribution," enhancing its risk resistance [3]. - The company has proposed a development strategy of "one body, two wings, and three depths," focusing on innovation while simultaneously transforming its marketing system and deepening industry chain integration [4]. - The marketing strategy includes a product matrix that combines "oral + external," "in-hospital + out-of-hospital," and "traditional dosage forms + high-end dosage forms," while actively expanding into third-party markets [4]. Product Development - Panlong Qipian, a core product included in the national medical insurance catalog, has been marketed for over 30 years, accumulating solid clinical evidence and reputation in the field of chronic pain treatment [4]. - The company is actively advancing multiple research and development projects to enrich its product pipeline, maintaining alignment with industry innovation and research investment [5].